Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological Activation of Hypoglossal Motor Nucleus for OSA
NCT03640052Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine + oxybutynin, LTM1201LN, LTM1201LB, LTM1201LD in obstructive sleep apnea (OSA), sponsored by Brigham and Women's Hospital. Started Oct 2018; status: completed.
02
Drugs
atomoxetine + oxybutyninLTM1201LNLTM1201LBLTM1201LD
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03640052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03640052.